Clinical trial NCT01703754: Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Official title: A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer Nos Metastatic Recurrent
Keywords: Genetically Modified Organism
Metastatic Breast Cancer
Recurrent Breast Cancer
Breast Cancer
Palifosfamide
INXN1001
INXN2001
Adenoviral vector
Lead sponsor: Alaunos Therapeutics
Sponsor class: INDUSTRY
First posted: 2012-10-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions.

Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with chemotherapy (palifosfamide) is safe and efficacious.

Detailed description: Multicenter, open-label, randomized study evaluating the safety and efficacy of INXN-1001 (veledimex) and INXN-2001 (Ad-RTS-hIL-12) alone and in combination with palifosfamide.

Part 1 is the safety run-in where a safety assessment will be made after 1 cycle of therapy.

Part 2, eligible subjects will be randomly assigned to active treatment Arms A or C.

Once the monotherapy (Arm A) is determined to be safe and tolerable, Part 1 combination therapy (Arm C) will begin.

Subjects should receive six cycles of study treatment, in the absence of meeting withdrawal criteria.

Eligibility criteria: Inclusion criteria:

1. Males or females ≥ 18 years of age
2. Histologically or cytologically confirmed adenocarcinoma of the breast, either locally recurrent or metastatic disease with injectable lesions, for which no proven curative therapy exists.
3. Failed or progressed on at least 1 prior systemic chemotherapy regimen ± biologic/experimental therapy (if first-line therapy, failure or progression during the first 30 days).
4. Resolution of all treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy ≤ Grade 2 and alopecia.
5. A minimum of 2 lesion(s) assessed by imaging using mRECIST v1.1.
6. Eastern Cooperative Oncology Group performance status 0, 1, 2
7. Male and female subjects must agree to use a highly reliable method of birth control.
8. Adequate bone marrow reserve as indicated by:

   1. Absolute neutrophil count \> 1500/μL (without use of growth factors within 7 days)
   2. Absolute lymphocyte count \> 700/μL (without use of growth factors within 7 days)
   3. Platelet count \> 100,000/mm3 (without transfusion in prior 7 days)
   4. Hemoglobin \> 9.0 g/dL (without transfusion in prior 7 days)
9. Estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation: eGFR ≥ 60 mL/min/1.73 m2
10. Adequate liver function as evidenced by the following:

    1. Bilirubin ≤ 1.5 times the upper limits of normal (ULN)
    2. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 2.5×ULN, in the case of liver metastases ≤ 5×ULN

Exclusion Criteria:

1. Subjects with human epidermal growth factor receptor 2 (HER2)/neu-positive (immunohistochemistry \[IHC\]) 3+ or fluorescence in situ hybridization-amplified) breast tumors who are eligible for, but who have not received HER2-targeted therapy (eg, trastuzumab)
2. Concomitant anticancer therapies
3. Prior therapies discontinuation periods:

   1. Radiation within 3 weeks of enrollment
   2. Chemotherapy within 4 weeks of enrollment
   3. Nitrosoureas within 6 weeks of enrollment
   4. Biologic therapy and/or immunomodulatory therapy, checkpoint inhibitors within 6 weeks of enrollment
   5. No washout period is required for endocrine therapy
4. Radiation therapy encompassing \>25% of bone marrow
5. History of bone marrow or stem cell transplantation
6. Any congenital or acquired condition leading to inability to generate an immune response
7. Immunosuppressive therapy:

   1. Systemic immunosuppressive drugs including corticosteroids (prednisone equivalent \>10 mg/day)
   2. Immune suppression/requiring immunosuppressive drugs, including organ allografts
   3. Active autoimmune disease requiring the equivalent of \>10 mg/day of prednisone
8. Major surgery within 4 weeks of study treatment
9. History of prior malignancy, unless the prior malignancy was diagnosed and definitively treated ≥5 years previously with no subsequent evidence of recurrence
10. Subjects with brain or subdural metastases, unless local therapy has completed and corticosteroids have been discontinued for this indication for ≥4 weeks before starting study treatment.
11. Any medications that induce, inhibit, or are substrates of cytochrome P450 (CYP450) 3A4 within 7 days prior to the first dose of study drug
12. Subjects with meningeal carcinomatosis
13. Known significant hypersensitivity to study drugs or excipients
14. History of malabsorption syndrome or other condition that would interfere with enteral absorption
15. International Normalized Ratio (INR) and activated partial thromboplastin time \[PTT\] \<1.5 x ULN, if not therapeutically anticoagulated.
16. New York Heart Association (NYHA) Class II or greater congestive heart failure OR active ventricular arrhythmia requiring medication
17. Any other unstable or clinically significant concurrent medical condition
18. Localized infection at site of injectable lesion(s) requiring antiinfective therapy within 2 weeks of the first dose of study drug.

Primary outcomes:
measure: Safety and tolerability of study drug therapy based on type and rate of adverse events and 16-week PFS rate.
timeFrame: Approximately 24 weeks-Beginning from the time a patient signs the informed consent to the Follow up Tumor Assessment visit
Secondary outcomes:
measure: Objective response rate (ORR) by modified RECIST v1.1
timeFrame: Approximately 24 weeks- From first study drug dose to Follow-Up Tumor Assessment Visit
measure: Clinical Benefit rate: proportion of subjects with CR, PR, or SD by modified RECIST v1.1
timeFrame: Approximately 24 weeks
measure: Estimate PFS by modified RECIST v1.1
timeFrame: Approximately 24 weeks, beginning at the first study drug administratrion and ending at the Follow up Tumor Assessment visit
measure: Evaluate Pharmacodynamic tumor markers in tumor tissue samples that may correlate with objective tumor response and/or clinical outcome
timeFrame: Approximately 24 weeks, starting with first study drug administrationa and ending at the Follow up Tumor Assessment visit
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Baptist Cancer Institute
state: Florida
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Billings
country: United States
facility: Billings Clinic
state: Montana
city: Middletown
country: United States
facility: Signal Point Clinical Research Center
state: Ohio
city: Greenville
country: United States
facility: Greenville Hospital System
state: South Carolina
city: Germantown
country: United States
facility: The Jones Clinic, PC
state: Tennessee
city: Dallas
country: United States
facility: Mary Crowley Medical Research Center
state: Texas
city: Spokane
country: United States
facility: Evergreen Hematology & Oncology
state: Washington
Study officials:
affiliation: Ziopharm Oncology
name: Francois Lebel, MD
role: STUDY_DIRECTOR
References: